BRIAN WILSON: Open Payments
NPI 1265076376 · GARDENDALE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,045 in 41 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $122 · 2025 $1,045
Food & beverage: $1,045
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 8 | $241 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $135 |
| Novo Nordisk Inc | 4 | $92 |
| Axsome Therapeutics, Inc. | 3 | $85 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $80 |
| Ardelyx, Inc. | 3 | $76 |
| Amgen Inc. | 3 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Lundbeck LLC | 2 | $40 |
Products named: SHINGRIX, Kerendia, REXULTI, TRELEGY ELLIPTA, Auvelity, CAPLYTA, IBSRELA, Ozempic.
Industry payments across AL — which companies pay providers there.
